| pubmed-article:9569459 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9569459 | lifeskim:mentions | umls-concept:C0005821 | lld:lifeskim |
| pubmed-article:9569459 | lifeskim:mentions | umls-concept:C0002679 | lld:lifeskim |
| pubmed-article:9569459 | lifeskim:mentions | umls-concept:C0011744 | lld:lifeskim |
| pubmed-article:9569459 | lifeskim:mentions | umls-concept:C2004454 | lld:lifeskim |
| pubmed-article:9569459 | lifeskim:mentions | umls-concept:C0038952 | lld:lifeskim |
| pubmed-article:9569459 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:9569459 | lifeskim:mentions | umls-concept:C0487681 | lld:lifeskim |
| pubmed-article:9569459 | lifeskim:mentions | umls-concept:C0547047 | lld:lifeskim |
| pubmed-article:9569459 | lifeskim:mentions | umls-concept:C0205197 | lld:lifeskim |
| pubmed-article:9569459 | lifeskim:mentions | umls-concept:C1554962 | lld:lifeskim |
| pubmed-article:9569459 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:9569459 | pubmed:dateCreated | 1998-6-30 | lld:pubmed |
| pubmed-article:9569459 | pubmed:abstractText | Platelet transfusion support is required during bone marrow aplasia following ablative chemotherapy and bone marrow progenitor cell transplantation (BMT). Amphotericin-B is frequently given to these patients, both therapeutically and prophylactically, and has been described to have a negative impact on the results of platelet transfusions. We conducted a prospective study of the effect of amphotericin-B on transfused platelet recovery and survival in 81 BMT or acute leukaemia patients. One hundred and ninety-five platelet transfusions administered to 81 consecutive patients were analysed. The platelets were transfused 2 h after the completion of amphotericin-B. Using this schedule resulted in no effect of amphotericin-B on platelet recovery or survival, although platelet increments were modestly depressed in patients receiving high- vs. low-dose amphotericin-B. We conclude that the timing of amphotericin-B infusion be evaluated in patients demonstrating poor platelet recovery and survival. Transfusing platelets at least 2 h after the completion of amphotericin-B decreases the detrimental effect of this antifungal agent on transfused platelet recovery and survival. | lld:pubmed |
| pubmed-article:9569459 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9569459 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9569459 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9569459 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9569459 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9569459 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9569459 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:9569459 | pubmed:issn | 0958-7578 | lld:pubmed |
| pubmed-article:9569459 | pubmed:author | pubmed-author:OISOTT | lld:pubmed |
| pubmed-article:9569459 | pubmed:author | pubmed-author:FletcherRR | lld:pubmed |
| pubmed-article:9569459 | pubmed:author | pubmed-author:HusseinM AMA | lld:pubmed |
| pubmed-article:9569459 | pubmed:author | pubmed-author:BolwellB JBJ | lld:pubmed |
| pubmed-article:9569459 | pubmed:author | pubmed-author:ZuccaroKK | lld:pubmed |
| pubmed-article:9569459 | pubmed:author | pubmed-author:HoeltgeAA | lld:pubmed |
| pubmed-article:9569459 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9569459 | pubmed:volume | 8 | lld:pubmed |
| pubmed-article:9569459 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9569459 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9569459 | pubmed:pagination | 43-7 | lld:pubmed |
| pubmed-article:9569459 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:9569459 | pubmed:meshHeading | pubmed-meshheading:9569459-... | lld:pubmed |
| pubmed-article:9569459 | pubmed:meshHeading | pubmed-meshheading:9569459-... | lld:pubmed |
| pubmed-article:9569459 | pubmed:meshHeading | pubmed-meshheading:9569459-... | lld:pubmed |
| pubmed-article:9569459 | pubmed:meshHeading | pubmed-meshheading:9569459-... | lld:pubmed |
| pubmed-article:9569459 | pubmed:meshHeading | pubmed-meshheading:9569459-... | lld:pubmed |
| pubmed-article:9569459 | pubmed:meshHeading | pubmed-meshheading:9569459-... | lld:pubmed |
| pubmed-article:9569459 | pubmed:meshHeading | pubmed-meshheading:9569459-... | lld:pubmed |
| pubmed-article:9569459 | pubmed:meshHeading | pubmed-meshheading:9569459-... | lld:pubmed |
| pubmed-article:9569459 | pubmed:meshHeading | pubmed-meshheading:9569459-... | lld:pubmed |
| pubmed-article:9569459 | pubmed:meshHeading | pubmed-meshheading:9569459-... | lld:pubmed |
| pubmed-article:9569459 | pubmed:meshHeading | pubmed-meshheading:9569459-... | lld:pubmed |
| pubmed-article:9569459 | pubmed:meshHeading | pubmed-meshheading:9569459-... | lld:pubmed |
| pubmed-article:9569459 | pubmed:meshHeading | pubmed-meshheading:9569459-... | lld:pubmed |
| pubmed-article:9569459 | pubmed:meshHeading | pubmed-meshheading:9569459-... | lld:pubmed |
| pubmed-article:9569459 | pubmed:meshHeading | pubmed-meshheading:9569459-... | lld:pubmed |
| pubmed-article:9569459 | pubmed:meshHeading | pubmed-meshheading:9569459-... | lld:pubmed |
| pubmed-article:9569459 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9569459 | pubmed:articleTitle | Transfusing platelets 2 h after the completion of amphotericin-B decreases its detrimental effect on transfused platelet recovery and survival. | lld:pubmed |
| pubmed-article:9569459 | pubmed:affiliation | Cleveland Clinic Cancer Center, Cleveland Clinic Foundation, USA husseim@cesmtp.ccf.org | lld:pubmed |
| pubmed-article:9569459 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9569459 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9569459 | lld:pubmed |
